$MBIO
MUSTANG BIO, INC. Stock $mbio

$mbio Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000114420416134293 Filed on November 14, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.000M	$1.100M	$90.00K
YoY Change	1150.0%	1122.22%
% of Gross Profit
Research & Development	$6.830M	$500.0K	$500.0K
YoY Change	798.68%	0.0%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$7.830M	$1.670M	$658.0K
YoY Change	832.14%	153.8%
Operating Profit	-$7.831M	-$1.670M	-$658.0K
YoY Change	828.94%	153.8%
Interest Expense	-$920.0K	-$200.0K	-$60.00K
YoY Change	1214.29%	233.33%
% of Operating Profit
Other Income/Expense, Net	-$917.0K	-$200.0K	-$58.00K
YoY Change	1248.53%	244.83%
Pretax Income	-$8.750M	-$1.870M	-$720.0K
YoY Change	861.54%	159.72%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$8.748M	-$1.870M	-$716.0K
YoY Change	860.26%	161.17%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$346.9K	-$74.15K	-$28.55K
COMMON SHARES
Basic Shares Outstanding	13.08M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.50M	$11.10M
YoY Change
Cash & Equivalents	$27.50M	$11.12M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses	$0.00
Receivables
Other Receivables
Total Short-Term Assets	$27.50M	$11.12M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00
YoY Change
Total Long-Term Assets	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$27.50M	$11.12M
Total Long-Term Assets	$0.00	$0.00
Total Assets	$27.50M	$11.12M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$700.0K	$1.000M
YoY Change
Accrued Expenses	$500.0K	$1.200M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$300.0K	$2.000M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.223M	$4.869M
YoY Change	-21.94%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$2.900M
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$2.900M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.223M	$4.869M
Total Long-Term Liabilities	$0.00	$2.900M
Total Liabilities	$3.223M	$7.800M
YoY Change	-21.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$17.12M	-$8.372M
YoY Change	283.34%
Common Stock	$37.00M	$11.69M
YoY Change	25242.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$24.28M	$3.322M
YoY Change
Total Liabilities & Shareholders Equity	$27.50M	$11.12M
YoY Change

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$8.748M	-$1.870M	-$716.0K
YoY Change	860.26%	161.17%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$2.260M	-$570.0K	-$1.040M
YoY Change	326.42%	-45.19%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$2.000M
YoY Change		-100.0%
Cash From Investing Activities	$0.00	$0.00	-$2.000M
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	18.65M	11.68M	3.040M
YoY Change	3418.87%	284.21%
NET CHANGE
Cash From Operating Activities	-2.260M	-570.0K	-1.040M
Cash From Investing Activities	0.000	0.000	-2.000M
Cash From Financing Activities	18.65M	11.68M	3.040M
Net Change In Cash	16.39M	11.11M	0.000
YoY Change	-7039451398144001000.0%
FREE CASH FLOW
Cash From Operating Activities	-$2.260M	-$570.0K	-$1.040M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-58000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-374000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-100000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-1870000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-716000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3906000	USD
CY2015Q4	ck0001680048	Accrued Interest Related Party Current AccruedInterestRelatedPartyCurrent	168000	USD
CY2016Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	632000	USD
CY2015Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4869000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4129000	USD
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13080547	shares
CY2016Q3	us-gaap	Cash Cash	11118000	USD
CY2015Q4	us-gaap	Cash Cash	0	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	11118000	USD
CY2016Q3	us-gaap	Assets Assets	11118000	USD
CY2016Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1040000	USD
CY2016Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	2001000	USD
CY2015Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	3571000	USD
CY2016Q3	ck0001680048	Accrued Expenses Related Party Current AccruedExpensesRelatedPartyCurrent	750000	USD
CY2015Q4	ck0001680048	Accrued Expenses Related Party Current AccruedExpensesRelatedPartyCurrent	375000	USD
CY2016Q3	ck0001680048	Accrued Interest Related Party Current AccruedInterestRelatedPartyCurrent	446000	USD
CY2016Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	2927000	USD
CY2015Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2016Q3	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	0	USD
CY2015Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	190000	USD
CY2016Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	11693000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	146000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8372000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4466000	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	3322000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-4129000	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11118000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	0	USD
CY2016Q3	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	673000	USD
CY2015Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	0	USD
CY2016Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10962703	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10962703	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2000000	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2000000	shares
CY2016Q3	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	0	shares
CY2015Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	250000	shares
CY2016Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	569000	USD
CY2015Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	570000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1718000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1134000	USD
CY2016Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2015Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2147000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1101000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	88000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1814000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	174000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	1670000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	658000	USD
	us-gaap	Operating Expenses OperatingExpenses	3532000	USD
	us-gaap	Operating Expenses OperatingExpenses	3455000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1670000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-658000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3532000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3455000	USD
CY2016Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	46000	USD
CY2015Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	58000	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	220000	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	100000	USD
CY2016Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	156000	USD
CY2015Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	156000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-200000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3555000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10089269	shares
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10000000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10130338	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9990099	shares
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	90000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1025000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	17000	USD
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	375000	USD
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	250000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	278000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	99000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1866000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1042000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2000000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	11083000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	12984000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3042000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	11118000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	0	USD
CY2015Q1	us-gaap	Cash Cash	0	USD
CY2015Q3	us-gaap	Cash Cash	0	USD
	us-gaap	Stock Issued1 StockIssued1	190000	USD
	us-gaap	Stock Issued1 StockIssued1	1000	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	634000	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1363000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	500000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1500000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1000000	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	2000000	USD
	ck0001680048	Issuance Of Common Stock Founder Agreement Expenses IssuanceOfCommonStockFounderAgreementExpenses	274000	USD
	ck0001680048	Issuance Of Common Stock Founder Agreement Expenses IssuanceOfCommonStockFounderAgreementExpenses	0	USD
	ck0001680048	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	0	USD
	ck0001680048	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	-147000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt">Use of Estimates</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	274000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12446000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1363000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	500000	USD
CY2015Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	0	USD
CY2016Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3600000	USD
CY2015Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	USD
CY2015Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2016Q3	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0137	pure
	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0160	pure
CY2016Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	-673000	USD
	ck0001680048	Issuance Of Warrants In Conjunction With Notes Payable IssuanceOfWarrantsInConjunctionWithNotesPayable	-634000	USD
CY2015Q4	us-gaap	Notes Payable NotesPayable	0	USD
CY2016Q3	us-gaap	Notes Payable NotesPayable	2927000	USD
CY2015Q3	ck0001680048	Percentage Of Warrants Issued On Outstanding Note Amount PercentageOfWarrantsIssuedOnOutstandingNoteAmount	0.25	pure
CY2015Q3	ck0001680048	Class Of Warrants Or Rights Issued Warrants Term ClassOfWarrantsOrRightsIssuedWarrantsTerm	P10Y
CY2016Q3	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
CY2016Q3	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P10Y
	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P9Y9M18D
CY2016Q3	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.7670	pure
	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.7670	pure
CY2016Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2000	USD
CY2015Q4	ck0001680048	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	670191	shares
CY2016Q3	ck0001680048	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding	670191	shares
CY2015Q4	ck0001680048	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instrument Other Than Options Outstanding Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice	0
CY2016Q3	ck0001680048	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instrument Other Than Options Outstanding Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice	8.50
CY2016Q3	ck0001680048	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instrument Other Than Options Granted Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice	8.50
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P0Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P5Y
	ck0001680048	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Granted In Period Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms	P5Y
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000	shares
	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	1400000	USD
CY2016Q2	ck0001680048	Founders Agreement Term FoundersAgreementTerm	P15Y
CY2016Q2	ck0001680048	Additional Consideration Under Founders Agreement Description AdditionalConsiderationUnderFoundersAgreementDescription	(i) pay an equity fee in shares of common stock, payable within five business days of the closing of any equity or debt financing for Mustang or any of its respective subsidiaries that occurs after the effective date of the Mustang Founders Agreement and ending on the date when Fortress no longer has majority voting control in the Company’s voting equity, equal to 2.5% of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to 4.5% of the Company’s annual net sales, payable on an annual basis, within ninety days of the end of each calendar year. In the event of a Change in Control, the Company will pay a one-time change in control fee equal to five times the product of (A) net sales for the twelve months immediately preceding the change in control and (B) 4.5%.
	ck0001680048	Proceeds From Issuance Of Notes Payble Discount ProceedsFromIssuanceOfNotesPaybleDiscount	-129000	USD
	ck0001680048	Proceeds From Notes Payable Gross ProceedsFromNotesPayableGross	3600000	USD
	ck0001680048	Proceeds From Notes Payable Gross ProceedsFromNotesPayableGross	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	3471000	USD

Files In Submission

Name	View Source	Status
0001144204-16-134293-index-headers.html	Edgar Link	pending
0001144204-16-134293-index.html	Edgar Link	pending
0001144204-16-134293.txt	Edgar Link	pending
0001144204-16-134293-xbrl.zip	Edgar Link	pending
ck0001680048-20160930.xml	Edgar Link	completed
ck0001680048-20160930.xsd	Edgar Link	pending
ck0001680048-20160930_cal.xml	Edgar Link	unprocessable
ck0001680048-20160930_def.xml	Edgar Link	unprocessable
ck0001680048-20160930_lab.xml	Edgar Link	unprocessable
ck0001680048-20160930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v452461_10q.htm	Edgar Link	pending
v452461_ex10-1.htm	Edgar Link	pending
v452461_ex10-2.htm	Edgar Link	pending
v452461_ex31-1.htm	Edgar Link	pending
v452461_ex31-2.htm	Edgar Link	pending
v452461_ex32-1.htm	Edgar Link	pending
v452461_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MBIO
MUSTANG BIO, INC. Stock $mbio

2016 Q4 Form 10-Q Financial Statement

#000114420416134293 Filed on November 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBIO MUSTANG BIO, INC. Stock $mbio

2016 Q4 Form 10-Q Financial Statement

#000114420416134293 Filed on November 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBIO
MUSTANG BIO, INC. Stock $mbio